Association Between the XRCC1, GSTM1, and GSTT1 Polymorphisms in Model of Thyroid Cancer: A Meta-Analysis

Abstract

Thyroid cancer is the most common malignant tumor of the endocrine system, and its incidence is increasing worldwide each year. This study aimed to explore the association between XRCC1, GSTM1, and GSTT1 polymorphisms in the model of thyroid cancer. The experiment was conducted by searching PubMed, Embase, and Web of Science, with the last search performed in March 2022. A total of 12 studies were included in this meta-analysis, with sample sizes ranging from 211 to 1124. The proportion of XRCC1 polymorphisms (rs25489, GG) in thyroid cancer was slightly lower than that of the normal control group, but the difference was not statistically significant (Mean difference=1.13, 95% CI: 0.99–1.28, p=0.08). The proportion of XRCC1 polymorphisms (rs25489, GA) in thyroid cancer was significantly lower than that of the normal control group (Mean difference=1.32, 95% CI: 1.16–1.52, p<0.00001). The proportion of XRCC1 polymorphisms (rs25489, AA) in thyroid cancer was slightly lower than that of the normal control group, but again, the difference was not statistically significant (Mean difference=0.78, 95% CI: 0.61–1.01, p=0.06). Similarly, the proportion of XRCC1 polymorphisms (rs25487, GG) and (rs25487, GA) in thyroid cancer was lower than that of the normal control group, but the differences were not statistically significant (p=0.22 and p=0.49, respectively). In conclusion, this study found that the proportion of XRCC1 polymorphisms (rs25489, AA) in thyroid cancer was lower than that of the normal control group.

Key words

XRCC1 - GSTM1 - GSTT1 - thyroid cancer - meta-analysis

Publication History

Received: 22 December 2022

Accepted after revision: 17 July 2023

Article published online:
07 September 2023

• References

• 1 Basté Rotllan N. Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer. Cancer Med 2022; 11: 10-16
• 2 Berciano-Guerrero M. Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer. Cancer Med 2022; 11: 40-46
• 3 Jimenez-Fonseca P. Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory-differentiated thyroid cancer. Cancer Med 2022; 11: 17-25
• 4 Hei H, Zhou B, Gong W. et al. Preoperative prediction of central neck metastasis in patients with clinical T1-2N0 papillary thyroid carcinoma. Sur Today 2022; 53: 507-512
• 5 Herranz UA. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer. Cancer Med 2022; 11: 47-53
• 6 Jensen K, Bikas A, Patel A. et al. Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells. Cancer Cell Int 2017; 24: 147-156
• 7 Klubo-Gwiezdzinska J, Costello J, Jensen K. et al. Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models. Endocr Connect 2017; 6: 469-478
• 8 Shinderman-Maman E, Cohen K, Moskovich D. et al. Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer. Sci Rep 2017; 7: 16475
• 9 Signore A, Campagna G, Marinaccio J. et al. Analysis of short-term and stable DNA damage in patients with differentiated thyroid cancer treated with (131)I in hypothyroidism or with recombinant human thyroid-stimulating hormone for remnant ablation. Sci Rep 2022; 63: 1515-1522
• 10 Sigurdson AJ, Hauptmann M, Alexander BH. et al. DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals. Mutat Res 2005; 586: 173-188
• 11 Wang Y, Yang L, Mao L. et al. SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways. Oncogene 2022; 22: 74
• 12 Abdel Ghafar MT. Impact of XRCC1 genetic variants on its tissue expression and breast cancer risk: A case-control study. Asian Pac J Cancer Prev 2021; 62: 399-408
• 13 London RE. XRCC1 – Strategies for coordinating and assembling a versatile DNA damage response. DNA Repair (Amst) 2020; 93: 102917
• 14 El-Rashidy MA, Gharib F, Al-Ashmawy GM. et al. XRCC1 deficiency correlates with increased DNA damage and male infertility. Environ Mol Mutagen 2019; 839: 1-8
• 15 Naguib M, Helwa MM, Soliman MM. et al. XRCC1 Gene polymorphism increases the risk of hepatocellular carcinoma in Egyptian population. Asian Pac Cancer Prev 2020; 21: 1031-1037
• 16 Liu SY, Xue W. XRCC1 Arg194Trp polymorphism and thyroid cancer. J Endocrinol Invest 2020; 43: 749-753
• 17 Gu Y, Zhao J, Ao L. et al. The influence of polymorphic GSTM1 gene on the increased susceptibility of non-viral hepatic cirrhosis: evidence from observational studies. Eur J Med Res 2018; 23: 34
• 18 Hu XY, Huang XY, Ma J. et al. GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis. Tumour Biol 2016; 37: 151-162
• 19 Nair RR, Khanna A, Singh K. Association of GSTT1 and GSTM1 polymorphisms with early pregnancy loss in an Indian population and a meta-analysis. Reprod Biomed Online 2013; 26: 313-322
• 20 Liu Y, Xu LZ. Meta-analysis of association between GSTM1 gene polymorphism and cervical cancer. OMICS 2012; 5: 480-484
• 21 Li D, Wang B, Feng G. et al. Effect of the GSTM1 genotype on the biomarkers of exposure to polycyclic aromatic hydrocarbons: meta-analysis. Int J Occup Med Environ Health 2017; 30: 177-201
• 22 Chanhom N, Udomsinprasert W, Chaikledkaew U. et al. GSTM1 and GSTT1 genetic polymorphisms and their association with antituberculosis drug-induced liver injury. Biomed Rep 2020; 12: 153-162
• 23 Xiao ZS, Li Y, Guan YL. et al. GSTT1 polymorphism and breast cancer risk in the Chinese population: an updated meta-analysis and review. Int J Clin Exp Med 2015; 8: 6650-6657
• 24 Song L, Yang C, He XF. Individual and combined effects of GSTM1 and GSTT1 polymorphisms on colorectal cancer risk: an updated meta-analysis. Biosci Rep 2020; 40: BSR20201927
• 25 Zhou TB, Drummen GP, Jiang ZP. et al. GSTT1 polymorphism and the risk of developing prostate cancer. Am J Epidemiol 2014; 180: 1-10
• 26 Pu Z, Wang Q, Xie H. et al. Clinicalpathological and prognostic significance of survivin expression in renal cell carcinoma: a meta-analysis. Oncotarget 2017; 8: 19825-19833
• 27 García-Quispes WA, Pérez-Machado G, Akdi A. et al. Association studies of OGG1, XRCC1, XRCC2 and XRCC3 polymorphisms with differentiated thyroid cancer. Mutat Res 2011; 709-710: 67-72
• 28 Ho T, Li G, Lu J. et al. Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case-control analysis. Thyroid 2009; 19: 129-135
• 29 Yan L, Li Q, Li X. et al. Association studies between XRCC1, XRCC2, XRCC3 polymorphisms and differentiated thyroid carcinoma. Cell Physiol Biochem 2016; 38: 1075-1084
• 30 Hernández A, Xamena N, Surrallés J. et al. Role of GST and NAT2 polymorphisms in thyroid cancer. J Endocrinol Invest 2008; 31: 1025-1031
• 31 Stankov K, Landi S, Gioia-Patricola L. et al. GSTT1 and M1 polymorphisms in Hürthle thyroid cancer patients. Cancer Lett 2006; 240: 76-82
• 32 Gaspar J, Rodrigues S, Gil OM. et al. Combined effects of glutathione S-transferase polymorphisms and thyroid cancer risk. Cancer Genet Cytogenet 2004; 151: 60-67
• 33 Zhu J, Qi P, Li Z. Interaction between XRCC1 gene polymorphisms and obesity on susceptibility to papillary thyroid cancer in Chinese Han population. Cell Physiol Biochem 2018; 49: 638-644
• 34 Kirnap NG, Tutuncu NB, Yalcin Y. et al. GA Genotype of the Arg280His polymorphism on the XRCC1 gene: genetic susceptibility genotype in differentiated thyroid carcinomas?. Balkan J Med Genet 2021; 24: 73-80
• 35 Reis AA, Silva DM, Curado MP. et al. Involvement of CYP1A1, GST, 72TP53 polymorphisms in the pathogenesis of thyroid nodules. Genet Mol Res 2010; 9: 2222-2229
• 36 Wang X, Zhang K, Liu X. et al. Association between XRCC1 and XRCC3 gene polymorphisms and risk of thyroid cancer. Int J Clin Exp Pathol 2015; 8: 3160-3167
• 37 Ryu RA, Tae K, Min HJ. et al. XRCC1 polymorphisms and risk of papillary thyroid carcinoma in a Korean sample. J Korean Med Sci 2011; 26: 991-995
• 38 Tcheandjieu C, Cordina-Duverger E, Mulot C et al. Role of GSTM1 and GSTT1 genotypes in differentiated thyroid cancer and interaction with lifestyle factors: results from case-control studies in France and New Caledonia. PLoS One 2020; 15: e0228187
• 39 Sambo M. Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer. Cancer Med 2022; 11: 26-32
• 40 Shu T, Xu S, Ju X. et al. Effects of systemic lidocaine versus dexmedetomidine on the recovery quality and analgesia after thyroid cancer surgery: a randomized controlled trial. Pain Ther 2022; 11: 1403-1414
• 41 Zafón C, Castelo B. Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios. Cancer Med 2022; 11: 3-4
• 42 Martínez-Trufero J. Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine-refractory differentiated thyroid cancer. Cancer Med 2022; 11: 5-9
• 43 Wu Z, Miao X, Zhang Y. et al. XRCC1 is a promising predictive biomarker and facilitates chemo-resistance in gallbladder cancer. Front Mol Biosci 2020; 7: 70
• 44 Yogesh L, Aswath N. GSTM1 null polymorphism and palmar dermatoglypics in oral leukoplakia. Indian J Dent Res 2021; 32: 69-73
• 45 Nakanishi G, Pita-Oliveira M, Bertagnolli LS. et al. Worldwide systematic review of GSTM1 and GSTT1 null genotypes by continent, ethnicity, and therapeutic area. OMICS 2022; 26: 528-541
• 46 Aguilera I, Sousa JM, Núñez-Roldán A. Clinical relevance of GSTT1 mismatch in solid organ and hematopoietic stem cell transplantation. Hum Immunol 2013; 74: 1470-1473
• 47 Liu D, Liu Y, Ran L. et al. GSTT1 and GSTM1 polymorphisms and prostate cancer risk in Asians: a systematic review and meta-analysis. Tumour Biol 2013; 34: 2539-2544
• 48 Abdalhabib EK, Jackson DE. Combined GSTT1 null, GSTM1 null and XPD Lys/Lys genetic polymorphisms and their association with increased risk of chronic myeloid leukemia. Pharmgenomics Pers Med 2021; 14: 1661-1667